【产业新闻】全球最成功的10位生物技术亿万富翁

ranchgirl

按 生物技术产业是朝阳产业，自然会吸引许多投资，也会造就许多亿万富翁，那么世界最成功的生物技术产业富翁究竟是哪些人，最近Fiercebiotech通过调查分析，给出了世界上最富有的10位生物技术富翁。他们的资产少则十几亿美元，多则几百亿美元。这些人中，除了比尔盖茨靠创办微软成为世界首富，但近几年他与夫人创办的盖茨基金会把好几十亿美元投资到健康产业，主要是做公益慈善。这是很了不起的事业和胸怀。在这10位生物医药富豪中，也有华人的身影，出生上海，移民南非，后到美国发展的美籍华人陈宋雄凭借其非凡的创新创业能力，成功兴办二家生物技术公司，分别上市做大做强，最后再卖给欧美上市大公司，从而实现了83亿美元的财富资产。成了美国最富的华人。不过如果把中国医药行业的富人计算在内，估计也有人能入榜。看来这份统计排行还是不算太客观。

Fierce's 10 top biotech billionaires

They are already rich, so why spotlight billionaires like Microsoft Chairman Bill Gates and Teva Chairman Dr. Phillip Frost?

Well, the mega-wealthy have made an impact all over the biopharma world, from nourishing risky ideas in the lab with early financing to pushing major M&A activity in the industry. And it's worth taking stock of the companies and investigators that have won support from some of the savviest business minds on the planet. That's why.

For the first time, FierceBiotech has rounded up 10 deep-pocketed players whose names should ring a bell with our readers. And while the names may come as no surprise, what did strike me while writing this report was the sheer volume of biotech deals and efforts these billionaires have enabled. Check out where Peter Thiel and other wealthy Facebook folks have placed their biotech bets.

Peter Thiel


A search of the Forbes list of billionaires turns up dozens of names with ties to the pharma industry, yet we have decided to highlight the activities of those who have invested in innovative drug and biomedical research. Notice that some of the people made their fortunes in the tech industry, while others have dedicated their careers to building pharma businesses.

It doesn't happen often, but the biotech industry minted new millionaires over the past year as values of cancer drug developer Pharmacyclics ($PCYC) and Swiss health giant Roche ($RHHBY) jumped. What good can these and other 10-figure folks do in the sector?

Dr. Patrick Soon-Shiong


One VC investor told me that billionaires likely account for only a small slice of the funding stream for biotech startups. Yet as you will see in the profiles in this report, billionaires have stepped up with cash to back bold ideas in recent years as startups struggle to garner support from traditional institutional and government funders. In the cases of Gates and biotech mogul Dr. Patrick Soon-Shiong, their healthcare investments make instant headlines as reporters closely follow their business interests. That kind of publicity brings extra value.

The people on this list appear in the order of their estimated net worth from Forbes and, in one case, Bloomberg. Please let us know your thoughts about this list. -- Ryan McBride

ranchgirl

第一 Bill Gates $67 billion

A champion and multibillion-dollar benefactor of global health causes, Bill Gates and his foundation have partnered early and often with biotech companies, seeking breaking advances in science to snuff infectious diseases and other ailments afflicting the world's most vulnerable populations. Separate from his foundation, Gates has a growing portfolio of venture investments in biotech companies such as Nimbus Discovery and Foundation Medicine (a 2012 Fierce 15 company), both of which are focused on improving cancer treatment.

In biotech, the "Gates-backed" stamp carries weight. As a co-founder and leader of Microsoft ($MSFT), Gates helped pioneer personal computing and blazed an entrepreneurial path for Facebook CEO Mark Zuckerberg and other tech royals to follow. On top of being one of the great business innovators of all time, Gates attaches his name only to societal and health matters of great global importance. If a biotech wins his support, it instantly becomes part of the epic Gates story, which people around the world follow closely.

As Forbes reports, Gates' estimated $67 billion fortune makes him the second-richest man in the world. (Yet the $28-billion-plus he has given away makes him the most benevolent person around the globe.) It's hard to quantify exactly how much Gates has invested in biotech, not that the sheer dollar figures pack as much punch as the legitimacy his name has lent to a long list of new biotechnologies.

Gates has brought the spotlight to several deserving drug or diagnostics developers recently. In January, Gates and fellow billionaire Yuri Milner contributed to a $13.5 million extension of a Series B round at Cambridge, MA-based Foundation Medicine, which is commercializing a cancer diagnostic that screens patients for more than 200 gene mutations to guide personalized attacks on malignancies. In oncology, that funding built on Gates' 2011 seed investment in Nimbus Discovery, which uses computer-aided drug discovery to nail down compounds against cancer and inflammation.

Gates' participation in the seed round at Nimbus followed his $10 million investment in the chemistry software provider Schrödinger, which supports drug-discovery efforts at the startup with manpower and technology.

For biotech outfits working on next-gen treatments for infectious diseases, the Bill & Melinda Gates Foundation has become a viable funding source. In November the foundation headlined a syndicate behind a $13 million first-round financing for the MIT spinoff Visterra to develop a universal therapeutic against influenza. That deal came just weeks after nearby Genocea listed the Gates Foundation as one of the backers of a $30 million Series C round to fund work on a pipeline of T cell vaccines, including a lead candidate against herpes simplex virus-2. The foundation has also supported a much longer list of biotech outfits such as vaccines developers Tetragenics and Liquidia.

ranchgirl

第二 罗氏家族 Estimated combined wealth = $35 billion

Big Pharma fish behave a lot like sharks, gobbling up rivals in merger and acquisition deals to stay atop the industry's food chain, looking for any weaknesses in their targets along the way. Few public drugmakers are safe from M&A predators. Yet Roche has been virtually invulnerable to takeover attacks thanks to a cast of filthy rich shareholders in the bloodline of company founder Fritz Hoffmann-La Roche.

Roche stock has shot up more than 33% over the past 12 months, during which the company captured approvals for two new treatments against breast cancer, Perjeta and Kadcyla, both of which came from the prodigious oncology portfolio at its Genentech group.

Andre Hoffmann, Vice Chairman of the Board of Directors at Roche

A jump in the Swiss pharma giant's ($RHHBY) stock value has vaulted several Hoffmann heirs into the global billionaire club, where the Hoffmann-Oeri clan resides along with Roche-related rich folk from the Engelhorn family of Germany, Bloomberg reported in February. Combined, the news wire estimated, the two families are worth north of $35 billion. Yet what makes the Hoffmann-Oeri family stand out most is that they control at least half of the voting rights at Roche.

The voting rights give the family members unique clout at Roche and a deep interest in the drugmaker's future despite their lack of operational roles at the company. And the family pool would likely even drown a takeover attempt from Novartis, despite the fellow Swiss healthcare behemoth's ($NVS) significant ownership stake in Roche. Speculation of such an attempt rose after Maja Oeri removed her sizable interest in Roche from the family pool, Bloomberg reported, but Maja made clear that she would stay committed to an independent future for the drugmaker.

Trust the moneymen on this one. Andre Baladi, a student of the ownership arrangement based in Geneva, told the news service that the fate of Roche rests in the hands of the Hoffmann-Oeri clan and not even Novartis has the power to alter this.

"Although the family pool doesn't have the majority any more, that doesn't change the picture at all," Baladi told the news service. "You cannot take over Roche, it's practically impossible."

Though they lack the clout of the Hoffmann-Oeri family at Roche, the Engelhorn pharma dynasty brings its own interesting history. Industry mogul Curt Engelhorn brought his family riches through the 1998 sale of Corange--owner of German diagnostics provider Boehringer Mannheim and a majority stake of devicemaker DePuy--to Roche for $10.2 billion. Engelhorn, whose fortune Forbes estimated is worth $4 billion, is also the great-grandson of German chemical giant BASF founder Friedrich Engelhorn.

The Roche-related billionaires seem to shun the spotlight, but they don't need it to remain powerful players at the biopharma giant.

ranchgirl

第三 印度太阳药业创始人 Dilip Shanghvi $9.2 billion

The past decade has gone well for Sun Pharmaceutical founder Dilip Shanghvi. Back in 2005 his fortune stood at $1.5 billion--a huge sum, but well short of the big hitters in India and beyond. Now, Shanghvi has swelled his fortune to $9.2 billion, making him the fifth Indian on the Forbes rich list. The $2.5 billion Shanghvi added to his wealth in the past 12 months made him, for the second year in succession, the biggest gainer among India's pharma elite.

Shanghvi's success is largely tied to his stewardship of Sun, which, since he founded it in 1982, has become a leading light among Indian drugmakers. Sun has attracted more headlines for its protracted, but ultimately unsuccessful, pursuit of Taro Pharmaceutical than anything else. But away from the Taro furor, Shanghvi has built a notable business. Sun has a bigger market cap than its local rivals and is highly profitable. Over the past 5 fiscal years, net profits at Sun have shot up by a compound annual growth rate of 27%.

With the Taro saga now, seemingly, finished, it is unclear how Shanghvi will try to maintain such growth. There is talk of Sun acquisitions in Brazil, Mexico or Russia--even murmurings of a $3 billion deal. Shanghvi threw gas on the gossip flames last year when he made the latest in a string of characteristically contrarian decisions. With Sun flying high, Shanghvi stepped down as chairman to hire a non-Indian, former Teva ($TEVA) CEO Israel Makov. Makov is known for growing Teva through acquisitions.

The move is something of a coup, but is highly unusual for an Indian company. Shanghvi, who is continuing as managing director, has been confounding others with left-field moves for decades. In the 1980s, when everyone else sold antibiotics to doctors, he began selling chronic pain meds to specialists. The bet paid off, and Shanghvi has continued to go against conventional wisdom.

"Eight out of ten times, Dilipbhai has a contrarian idea which has also turned out correct," Tarun Shah, partner at Mehta Partners, told Forbes. Through such contrarian ideas Shanghvi has maintained the growth of Sun in a period littered with difficulties. After two years butting up against hedge funds, Sun dropped its bid for the remaining third of Taro in February. And Sun has also contended with regulatory problems at its other driver of U.S. growth, Caraco. Despite these problems, Sun has added business in the U.S. When the FDA needed a drugmaker to help with the Doxil shortage, Sun stepped forward with its Lipodox generic.

ranchgirl

第四位 Hansjörg Wyss $8.7 billion

Hansjörg Wyss reached into his deep pockets last year to help revive the ailing biotech sector and life sciences scene in Geneva, building on his previous work to tap his fortune from the medical devices industry to bankroll foundational discoveries in regenerative medicine and other biomedical fields.

In June, Wyss (pronounced Veese) sold his Swiss medical device manufacturer Synthes to Johnson & Johnson ($JNJ) for $20 billion, and Forbes estimates his personal fortune to be $8.7 billion, which makes him the second-richest man in Switzerland behind the family of Ernesto Bertarelli, who is heir to the Serono biotech fortune. But unfortunately Merck KGaA, which bought Serono in 2007, last year decided to pull the plug on the Geneva headquarters of the company.

After German Merck's move dealt a blow to the Swiss biotech scene, Wyss and Bertarelli teamed up with other local interests to purchase the R&D headquarters of Merck Serono in Geneva. Wyss' foundation plans to sink $100 million into the campus over 6 years to establish the Wyss Institute, a new hub of biotech and healthcare innovation. His bankroll is expected to fuel labs devoted to bioengineering and next-generation prosthetics.

The institute drew immediate comparisons to Harvard University's Wyss Institute for Biologically Inspired Engineering, which Wyss himself underwrote with a big $125 million gift in 2009, making it the largest in the history of the Ivy League school. Via the institute, Wyss has attached his name to some of the most prolific biotech inventors in the world, including Harvard chemist and Genzyme co-founder George Whitesides and Harvard geneticist George Church, a pioneer of genetic multiplexing.

With his checkbook, Wyss has shown that he endorses a brand of highly risky but groundbreaking biotech research that calls for experts from multiple fields to play roles in solving complex medical problems. And his philanthropic support of research at Harvard has already funded inventions such as a microchip model of the lung and drug-coated nanoparticles that could find use against multiple diseases.

ranchgirl

第五位 美国华人首富 陈宋雄

Dr. Patrick Soon-Shiong $8 billion

Movie moguls, meh. The man known as the richest person in Los Angeles made most of his moolah from the biopharma business.

Dr. Patrick Soon-Shiong has diversified his pharma fortune into industries such as sports and entertainment as well as many things digital via his company NantWorks. And, in addition to his existing stake in the LA Lakers, his name had landed on a short list of bidders for the real estate and sports powerhouse AEG before the sale process was jettisoned in recent weeks. But his non-pharma pursuits have in no way diminished his commitment to advancing next-generation patient treatments.

At NantWorks, Soon-Shiong maintains a strong interest advancing digital medicine and next-generation therapies. Early this year he came out with details about his cancer drug developer NantOmics. In July, Blackstone Group scooped up a $125 million stake in his related venture NantPharma, a maker and researcher of biologically derived drugs. And he has made either purchases or investments in diagnostics, digital medicine and other healthcare assets since he unveiled NantWorks in 2011.

If wannabe billionaires learn anything from the Soon-Shiong story, they should pay attention to how he seems to understand the value of biopharma assets and how they all complement each other better than anyone at the bargaining table. His skills in negotiation and evaluation showed in the sales of his APP Pharmaceuticals to Fresenius in 2008 for $5.6 billion and his APP spinoff Abraxis BioScience to Celgene ($CELG) in 2010 for $2.9 billion. Forbes estimates his fortune as of March at $8 billion.

Soon-Shiong spun off Abraxis from APP in 2007 and the biotech advanced Abraxane, the first nanoparticle albumin-bound cancer drug to gain FDA approval. After Celgene paid megabucks to acquire Abraxis, Soon-Shiong bought back a library of kinase inhibitors, which he is now developing at NantOmics.

Through various vehicles, Soon-Shiong has gained control of the 12,000-mile fiber-optic network of the National LambdaRail and established supercomputing capabilities to rapidly analyze data from tumor samples. The network can zap data from the computer analyses to physicians, who can then use the information to guide personalized treatments against cancer.

With NantOmics and assets from NantHealth, Soon-Shiong hopes to rapidly advance development of new combination therapies against cancer. And his network reaches some 8,000 oncologists, he recently told Bloomberg TV. So he has many pieces of his new healthcare empire in motion, and it will be interesting to watch how his latest ventures progress.

ranchgirl

第六位 Dietmar Hopp $6.5 billion

With a chunk of his SAP software riches, Dietmar Hopp has helped champion the growth of the biotech sector in Germany. Dievini Hopp BioTech Holding, his life sciences investment shop, touts a portfolio of 15 drug and diagnostics developers, and his bets on risky biotech outfits come as raising funds for such companies has tested the wills of many traditional backers of the sector in Europe and elsewhere.

So cash-hungry drug developers in Germany should celebrate the $1 billion jump in Hopp's fortune during the year leading up to March, when his estimated net worth came in at $6.5 billion thanks to growth in the value of SAP shares, Forbes reported.

Hopp, who co-founded SAP in the 1970s and previously served as its co-CEO, became a billionaire through decades of hard work in the software sector. Yet the high-tech industry churns out new products annually compared with a decade or more to commercialize a biotech therapy. That Hopp comes to the biotech game with a software background makes his patience and long-term commitment to development-stage biotech companies laudable.

Tubingen, Germany-based CureVac, for instance, tapped Hopp's dievini for an

ranchgirl

第七位 Dr. Phillip Frost $2.6 billion

Dr. Phillip Frost has an enviable track record in the building and selling of bio businesses. An early success came in 1986 when, 14 years after taking over then-nearly-bankrupt Key Pharmaceuticals with Michael Jaharis, he sold the company to Schering-Plough. In his role as chairman, Frost helped build Key into a consistently profitable company with sales north of $150 million a year. Frost is thought to have earned around $150 million from selling his stake.

The sale gave Frost the funds to found what was to become the company that defined him as a builder of biopharma businesses, Ivax. Founded in 1987, Ivax made a series of acquisitions in its early years and became a major player in the sale of generic pharmaceuticals. Ivax was ahead of the curve on the rise of emerging markets and built strong positions in Latin America, Central and Eastern Europe and the United Kingdom. This robust global footprint attracted the attention of buyers, and in 2006 Israeli generics giant Teva ($TEVA) bought Ivax for $7.4 billion. Again, Frost took home a sizable return on his initial investment.

While building Ivax from his position as chairman, Frost found the time to found North American Vaccine, by combining the assets of two existing companies, and then sell the firm to Baxter ($BAX). Yet again, Frost made a tidy profit from the $390 million in cash, stock and debt Baxter coughed up for the vaccinemaker. A more recent success story is Protalix Biotherapeutics: Frost was among the first investors in the company, but largely cashed out in 2011. Now, the rare disease model pursued by Protalix has seen it partner with Pfizer ($PFE) and generate talk of a $1 billion takeover.

It is possible Frost could have increased returns on Protalix by holding onto his shares for a few more years, but even so he has grown his net worth to $2.6 billion, according to Forbes. These repeated successes mean that now when Frost backs a company people take notice. And Frost gives them plenty of firms to track. The biggest play is Opko Health, which, in a move mirroring the formation of other Frost companies, was created in a roll-up of several firms. As with Ivax, Frost then took a managerial role and began buying and licensing assets, particularly after the failure of a key ophthalmology trial in 2009.

Frost is also chairman of Teva, having joined the firm in the takeover of Ivax, and has a stake in a handful of other companies in bio and beyond. Among these is Prolor Biotech, where Frost has a large shareholding and serves as chairman.

ranchgirl

第八位 Randal "RJ" Kirk $2.4 billion

RJ Kirk is one of the rare people in the world with a self-made fortune from biopharma, where he has beat the long odds with multiple major successes and has stayed deeply invested. He has a track record for finding juicy opportunities, seizing big stakes and then pushing the pharma operations toward value-building milestones from a position of authority.

As of March, Forbes estimated Kirk's fortune at $2.4 billion. In an industry where a lucky soul might become a millionaire from one winning venture, Kirk has sold two of his companies for more than $1 billion. Clinical Data ($CLDA), where he was chairman and controlled much of the stock, went to Forest Laboratories ($FRX) in 2011 for $1.2 billion. Earlier, in 2007, he engineered the $2.6 billion sale of New River Pharmaceutical to Shire ($SHPG).

Lately, he's bet heavily on synthetic biology, with a venture called Intrexon (a 2011 Fierce 15 company) that could become his biggest financial boon--or bust--ever. Serving as chairman, chief executive and, via his venture company Third Security, chief financier, Kirk has kept Intrexon well funded and busily securing deals with a constellation of players in drug development, aquaculture, animal health and agriculture. "Almost nothing is off limits with the power of this technology," Kirk told FierceBiotech in 2011.

Whereas New River became a multibillion-dollar hit based on its ADHD drug Vyvanse and Clinical Data a winner from the antidepressant Viibryd--both standalone products--Intrexon aims to create value from use of its biotech platforms across multiple different industries and partner companies. Intrexon's success depends in part on its partners' successes, and the company will surely feel the sting from any key partner's failure.

One of Intrexon's marquee partners isn't looking so hot. Ziopharm Oncology, which is Kirk's handpicked partner for Intrexon in cancer drug development, reported a major misfire as its advanced antitumor candidate palifosfamide failed a late-stage study for metastatic soft tissue sarcoma, prompting a meltdown of more than half of its stock value on March 26.

Yet Ziopharm CEO Jonathan Lewis reaffirmed his company's commitment to synthetic biology, which is obviously important to his influential board member RJ Kirk. "It is imperative that the company rapidly focus its resources and efforts on our highly promising synthetic biology programs, employing therapeutic motifs that represent the next-generation in biotechnology," he stated.

ranchgirl

第九位 Peter Thiel $1.6 billion

Peter Thiel is living proof that big bets on new technologies and investments can blossom with prodigious growth or fall flat. While his hedge fund hasn't impressed, his holdings in Facebook and PayPal have made the Stanford alum a billionaire, giving him the wealth to inject his risk-taking message and money into the biotech world.

In 2011 Thiel's eponymous foundation began the Breakout Labs program to fund startups with the kind of wild biotech ideas that scare off traditional institutional and government funders. Yet in his view these edgy startups--including one called Immusoft that is working on turning immune cells into drug factories and another by the name of Arigos that aims to cryogenically preserve organs prior to transplants--have the potential to bring radical change to medicine.

The nature of taking early risks in biotech is that many ideas won't pan out. Last year Thiel and fellow PayPal pal and Tesla chief Elon Musk were listed among the investors who tasted failure in biotech with bets on Halcyon Molecular, a member of the genomics herd that got trampled after running short of funds to advance faster and cheaper DNA sequencing tech. Yet Thiel has the capital to keep rolling in biotech.

Forbes estimated that Thiel is worth $1.6 billion. He cashed in handsomely on Facebook's IPO and earlier achieved tech scene master status as one of the early crew behind PayPal. (Thiel also invested early in FierceMarkets, the publisher of FierceBiotech, but sold his stake years ago.) Despite the success of his Founders Fund, the assets under management at his hedge fund Clarium Capital have dwindled.

In biotech, Thiel has set an example for other tech tycoons to follow--including much richer ones like Facebook cofounder and CEO Mark Zuckerberg. Early this year Zuckerberg joined Facebook investor Yuri Milner, Google cofounder Sergey Brin, Anne Wojcicki and others to bankroll research grants for the Breakthrough Prize in Life Sciences effort. They too want to seed breaking science.

ranchgirl

第十位 Robert Duggan $1.2 billion

Robert Duggan is the newest billionaire on our list. The Pharmacyclics CEO and life sciences veteran busted past the $1 billion mark after the value of his company's ($PCYC) shares tripled over the past year in the wake of progress with its experimental drug ibrutinib against chronic lymphocytic leukemia (CLL).

Duggan, who had megamillions from previous holdings prior to reaching billionaire status, was worth about $1.2 billion on paper as of last month, according to Forbes. The lion's share of his wealth hinges on the value of his 20% stake in his Sunnyvale, CA-based biotech, which was worth about $5.6 billion as of March 29.

He amassed the large interest in Pharmcyclics mostly from his personal investments in the company from 2004 to 2011 at a cost of $42 million, according to Bloomberg. He wrested control of the board in 2008, reaching into his own pocket to lend the company $6.4 million between December of that year and March 2009. Wisely, he took stock as repayment for the loans. Yet since he became chairman in September 2008, Duggan hasn't cost the company or its shareholders a dime, going sans salary or other compensation from Pharmacyclics.

The fate of his billionaire status rests with one drug. Ibrutinib, a compound designed to block Bruton's tyrosine kinase, has shown an ability to kick some cancer ass without severe side effects--an important feature of the therapy because 70% of the 15,000 or so patients diagnosed with CLL in the U.S. every year are elderly. In December the company reported that 71% of previously untreated patients and 67% of those with relapsed disease responded completely or partially to the therapy.

Based on earlier data, Johnson & Johnson ($JNJ) stepped up with a $975 million partnership pact with Pharmacyclics for a share of the potential spoils from ibrutinib sales, which analysts cited by Bloomberg have estimated could hit $5 billion. What is more, the FDA awarded the compound "Breakthrough" status earlier this year, meaning the treatment could gain a rapid approval without completing all three phases of development usually required to garner a market green light.

Like many of his fellow biotech billionaires, Duggan has worked in his industry for decades. He previously helmed the surgical robotics company Computer Motion until 2003, when the company merged with rival Intuitive Surgical. Bloomberg estimated that his non-Pharmacyclics fortune stands at about $250 million, so he won't be in the poorhouse if ibrutinib tanks.

ranchgirl

去年这个时候，大家还沉浸在对海普瑞上市之后的震动之中。一家鲜为人知的公司，忽然间，攫取了中国财富榜的魁首，对很多人来说，接受起来需要时间。

　　果然，海普瑞，从188元跌到了105元，险些破百。有一些知名人士说，海普瑞是一个泡沫，甚至是一个骗局，所以它应

相关公司股票走势





该被打回原形。

　　然而什么原形呢？我想很多人未必是知道的，我们自然也不知道，因为这个行业实在是太过于繁杂了。我们唯一知道的事情，就是他做出来的业绩。

　　这种的话很多，泛着酸味。海普瑞上市之时的狂欢，到底是不是一种泡沫？即便是泡沫，它也透亮的映着中国老一批富豪们创造力的衰退和中国新兴行业的脆弱。在中国，食品饮料和医药行业，必将是富豪如过江之鲫崛起的潮涌之地。

　　你若不信，为何医药行业竟然诞生了如此多的首富呢？

　　那些医药行业里出来的首富

　　现在李锂夫妇的财富是237亿，虽然这个数字比去年最高的541亿缩了一大半，李锂也不再是中国首富，但是他仍旧牢牢盘踞着医药行业的老大位置。

　　而且很多人相信，李锂的财富只会增加，不会减少。一旦摆脱高盛这个影子，李锂的事业将有一轮新的爆发。他很有可能在不远的未来，超过马化腾，成为深圳首富。——当然，短期内要超过那帮脑满肠肥的广东地产大佬，从而成为广东首富，或许还是有难度的。

　　李锂的光环遮蔽了很多的隐形首富。

　　譬如说，生物医药的榜眼，科伦药业的刘革新，财富113.64亿。这个数已经远远超过了当年的豪门，新希望刘永好家族。

　　实际上，刘革新做企业，45岁才出道，和很多人一样，都是被迫离开光鲜的大公司高级岗位。1995年年底，刘革新离开了供职4年的某中美合资制药企业。这位前任总经理辞职前甩给美国老板们这样一句话：如果你们还这样对待中国员工，我会让你们一辈子都生活在我的阴影之下；我会干和你们一样的事情，我会证明中国人的能力绝对超越你们。

　　探花刘宝林家族，以九州通上市实现的109亿财富，也雄踞荆楚大地。湖北近年在资本界籍籍无名，在资本市场的表现也相当的不给力，衰老的工业经济让这块沃土倍感寂寥。因此近些年，湖北很少出大富豪，尤其是拿得出手的新一代富豪，谁都没想到，这个超百亿的人出现在一个原来的赤脚医生身上。

　　刘宝林的创富志说明，老工业基地衰落就衰落了，但是背后的底子是永远不落的。他就是利用了武汉四通八达的物流网络做成了一个九州通。想想，其实没有太多的技术含量，但是能做成这样的规模，自然工夫在诗外。

　　排在第八位的姜伟，据说是一位有精神偏执的人。只有这样的人，才能把一个苗药厂带出来，把自己做成贵州省首富。在贵州那个神奇的地方，创业需要相当的勇气和毅力，做大事则需要更多更多的东西。

　　在贵州，所有的财富都是跟吃有关的。贵州茅台自不用说了，然而它创造的财富是国家的。其次是著名的老干妈，真的，它是贵州第二品牌。然后现在是贵州百灵，做药的。这个地方的财富充分说明，在人类的基本需求面前，其他一切繁华都是浮云。

　　第九名的安康家族，去年以115亿排在第二位，今年缩水了部分，仅有72亿，部分原因是市场调整，部分原因则是他减持了部分股权。但这不妨碍安康家族继续当河南首富。河南也是一片神奇沃土，产出的公司，要么冠绝天下，要么死水一滩。华兰生物所从事的疫苗和血液制品行业，为医药行业这个朝阳行业中的朝阳行业，被市场广为看好。

　　第十位蒋仁生，也是一个首富。不过不是区域首富，是创业板首富。智飞生物也是从事的疫苗行业，备受关注。值得注意的是，这家公司不但造就了蒋仁生一人，还造就了数位财富不菲的亿万富豪。包括其合作伙伴吴冠江，就以30亿财富排在27位。

　　致富的传奇色彩

　　还没完。

　　奇正藏药的董事长雷菊芳家族，当初心情郁闷跑去西藏打算清修，结果一不留神修炼成了西藏首富。她的财富现在是69.93亿元。这是一个神奇的公司，十多年来，奇正藏药的发展基本不依靠银行贷款，雷菊芳认为，专注主业才是成功关键，公司的滚动发展对公司至关重要。

　　雷菊芳的老乡，独一味的阙文彬家族，以41.95亿元成为甘肃首富。现年46岁的甘肃独一味生物制药股份有限公司董事长阙文彬在业界具有传奇色彩：1996年,33岁的阙文彬在西藏考察时发现了独一味。正如毛主席所言，时间无难事，只怕有心人。

　　最后一位要提到的首富，可能大家一不留神就会忘记他。那就是江湖大佬复星医药的郭广昌先生。

　　郭广昌通过复星医药持有的财富是47.529亿元，但这不算什么。因为郭广昌的复星系实在是太过于庞大，有时人们都怀疑郭广昌能够记得自己有多少家子公司孙公司。不管怎样，郭广昌的事业，生于医药，起飞于医药，未来也瞩目于医药。到目前为止，与复星有资产关联的上市公司已经有5家，即复星医药、豫园商城(600655)、友谊股份(600827)、羚锐制药(600285)和天药股份(600488)。为什么说郭广昌是首富呢？因为，他的真实财富在目前的上海滩，尚无其匹。并且，他本是浙江东阳人，虽然老郭淡出乡土多年，但家乡人总以浙江首富诩之，亦不能言错吧。